Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.

Saved in:
Bibliographic Details
Title: Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Authors: Stein Gold L; Henry Ford Medical Center, Detroit, Michigan. Electronic address: lstein1@hfhs.org., Adam DN; CCA Medical Research, Toronto, Ontario, Canada; Probity Medical Research, Toronto, Ontario, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Albrecht L; Enverus Medical Research, Surrey, British Columbia, Canada., Alonso-Llamazares J; Driven Research LLC, Coral Gables, Florida., Ferris LK; Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania., Gooderham MJ; SkiN Centre for Dermatology, Peterborough, Ontario, Canada; Probity Medical Research, Peterborough, Ontario, Canada; Queen's University, Peterborough, Ontario, Canada., Hong HC; Probity Medical Research, Surrey, British Columbia, Canada; Department of Dermatology and Skin Science, University of British Columbia, Surrey, British Columbia, Canada., Kempers SE; Minnesota Clinical Study Center, Fridley, Minnesota., Kircik LH; Icahn School of Medicine at Mount Sinai, New York, New York; Indiana Medical Center, Indianapolis, Indiana; Physicians Skin Care, PLLC, Louisville, Kentucky; Skin Sciences, PLLC, Louisville, Kentucky., Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, New York., Loo WJ; DermEffects, London, Ontario, Canada; Probity Medical Research, London, Ontario, Canada; Western University, London, Ontario, Canada., Nahm WK; University of California, San Diego, School of Medicine, San Diego, California., Papp KA; Probity Medical Research, Waterloo, Ontario, Canada; Alliance Clinical Trials, Waterloo, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada., Stewart D; Michigan Center for Skin Care Research, Clinton Township, Michigan., Toth DP; XLR8 Medical Research, Windsor, Ontario, Canada; Probity Medical Research, Windsor, Ontario, Canada., Zirwas M; Dermatologists of the Central States, Bexley, Ohio; Probity Medical Research, Bexley, Ohio; Ohio University, Bexley, Ohio., Krupa D; Arcutis Biotherapeutics, Inc., Westlake Village, California., Snyder S; Arcutis Biotherapeutics, Inc., Westlake Village, California., Burnett P; Arcutis Biotherapeutics, Inc., Westlake Village, California., Higham R; Arcutis Biotherapeutics, Inc., Westlake Village, California., Berk DR; Arcutis Biotherapeutics, Inc., Westlake Village, California.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Aug; Vol. 91 (2), pp. 273-280. Date of Electronic Publication: 2024 Mar 29.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6787
DOI:10.1016/j.jaad.2024.03.030